Longeveron第二季度每股亏损0.19美元

投资观察
Aug 13

美国生物科技公司Longeveron Inc(股票代码:LGVN)于8月12日披露了其第二季度财务数据。该季度运营支出达到635.3万美元,而每股收益则录得-0.19美元。这一数字揭示了公司在研发及运营方面的持续投入情况。尽管Longeveron目前尚未实现盈利,但其在再生医学领域的探索仍在持续推进,尤其针对衰老相关疾病的研究。投资者需密切关注其未来现金流表现及管线进展。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10